ESCRS - FPS11.02 - Efficacy Of Autologous Platelet Rich Plasma (Prp) Eye Drops In Refractory Dry Eye Disease (Ded) Patients

Efficacy Of Autologous Platelet Rich Plasma (Prp) Eye Drops In Refractory Dry Eye Disease (Ded) Patients

Published 2022 - 40th Congress of the ESCRS

Reference: FPS11.02 | Type: Free paper | DOI: 10.82333/j6mf-dc83

Authors: Manokamna Agarwal 1 , Nizar Din 1 , Larissa Gouvea 1 , Clara Chan 1 , Bruce Jackson 2 , Allan Slomovic* 1

1Department of Ophthalmology and Visual Sciences,Toronto Western Hospital, University of Toronto,Toronto,Canada, 2Department of Ophthalmology,Peterborough Regional Health Centre,Peterborough,Canada

Purpose

To evaluate change in objective and subjective parameters of Dry Eye with use of PRP eye drops in refractory DED.

Setting

University of Toronto, Department of Ophthalmology and Visual Science, Toronto, Ontario, Canada. 

Methods

We treated 40 patients of DED (mean age 64.05 ± 16.17 yrs, Female=33, Male=07) with PRP eye drops who were unresponsive to previous other therapies The patients were divided into 2 groups, Group 1- Aqueous Deficient Dry Eye (ADDE) group (n=20), and Group 2- Evaporative Dry Eye (EDE) group (n=20), based on DEWS II criteria. Best corrected visual acuity (BCVA), non-invasive tear film breakup (NIBUT), Schirmer 1 test (ST), Lissamine Staining Score (LSS), Fluorescein staining (FS), meibomian gland disease (MGD) as per JENVIS grading scale, and Ocular surface Disease Index (OSDI) score were recorded pre and post treatment. Additionally, SANDE questionnaire is also used for post treatment subjective evaluation.

Results

In all patients, apart from conventional therapy, following therapies were tried before PRP eye drops. Cyclosporin 0.05% in 80%(16) & 35%(7), Lifitegrast 5% in 55%(11) & 40%(8), low dose steroid in 45%(9) & 25%(5), serum tears in 65%(13) & 40%(8), scleral lens in 20%(4) & 5%(1), IPL therapy in 15%(3) & 55%(11), lipiflow in 5%(1) & 30%(6), and punctal plugs in 5%(1) & 0% in group 1 & 2 respectively. Pre-PRP treatment values (Median/IQR) for BCVA(logMAR) was 0.20(0.2-0.4) & 0.1(0-0.35), NIBUT(sec) was 4.9(4.15-6.5) & 5.2(3.8-10.1), ST(mm) was 5(0-8) & 16.5(9.5-21), LSS was 6.5(3-8) & 1(0.75-3.75), FS was 2(1-2) & 1(0-3), MGD grade was 3(2.5-3) & 3(3-3), and OSDI score was 45.8(43.18-66.67) & 56.25(49.48-61.93) in group 1 & 2 respectively.

Conclusions

Our preliminary analysis of post PRP eye drops treatment in initially enrolled patients appears to have improvement in objective and subjective parameters for DED. Our mean follow-up is 7.7±5.8 months till date. We are in process of analyzing the results for recently enrolled patients. Financial Disclosure: none.